Author

H.-Christian von Büdingen

Observed names: H. -Christian von Büdingen, H. Christian von Büdingen, H.-C. Büdingen, H.-C. von Büdingen, H.-Christian Von Büdingen, H.-Christian von Büdingen, H.C. von Büdingen, Hans Christian von Büdingen, von Büdingen, H‐Christian

Institution: Roche (Switzerland)

Observed institutions: Roche (Switzerland), University of California, San Francisco, Genentech, University of Zurich, TUM Klinikum, John Radcliffe Hospital, University of Oxford, McGill University, Technical University of Munich

OpenAlex ID: A5108921358

Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis

2024 · Anne H. Cross, Jeffrey M. Gelfand, et al. · JAMA Neurology · 104

PDF

IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis

2019 · A. Francesca Setiadi, Alexander R. Abbas, et al. · Journal of Neuroimmunology · 93

An autoantibody signature predictive for multiple sclerosis

2024 · Colin R. Zamecnik, Gavin M. Sowa, et al. · Nature Medicine · 91

PDF

Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

2022 · Takashi Yamamura, Brian Weinshenker, et al. · Multiple Sclerosis and Related Disorders · 63

PDF

Intrathecal B-cell activation in LGI1 antibody encephalitis

2020 · Klaus Lehmann-Horn, Sarosh R. Irani, et al. · Neurology Neuroimmunology & Neuroinflammation · 41

PDF

Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial

2023 · Sarah A. Laurent, Nicolas B. Strauli, et al. · Neurology Neuroimmunology & Neuroinflammation · 16

PDF

Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series

2022 · Takashi Yamamura, Manabu Araki, et al. · Multiple Sclerosis and Related Disorders · 16

Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies

2021 · Michael Levy, Alan R. Haycox, et al. · Multiple Sclerosis and Related Disorders · 16

Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study (S56.008)

2019 · Anne Cross, Jeffrey Bennett, et al. · Neurology · 16

Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study

2019 · A. Traboulsee, B. Greenberg, et al. · Journal of the Neurological Sciences · 13

Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD)

2019 · Jeffrey L. Bennett, B. Greenberg, et al. · Journal of the Neurological Sciences · 5

PDF

Progenitor Cell Therapy for Neurological Injury

2011 · H.-Christian von Büdingen · Archives of Neurology · 5

Adolescents with NMOSD Achieved Similar Exposures and Favorable Safety Profile when Treated with the Adult Satralizumab Dosing Regimen (1492)

2020 · Cheryl Hemingway, Hanna Silber Baumann, et al. · Neurology · 4

Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006)

2026 · Michael Levy, Eoin Flanagan, et al. · Neurology · 3

Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)

2026 · Jiwon Oh, Amit Bar-Or, et al. · Neurology · 1

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)

2026 · Amit Bar-Or, Jiwon Oh, et al. · Neurology · 1

Evaluation of CHIT1 and SERPINA3 as Candidate Cerebrospinal Fluid Biomarkers of Progressive Biology in Multiple Sclerosis (S33.003)

2025 · Amit Bar-Or, Jeffrey Gelfand, et al. · Neurology · 1

B-Zell-gerichtete Multiple-Sklerose-Therapie

2009 · T. Menge, H.-C. Büdingen, et al. · Der Nervenarzt · 1

Preclinical B cell depletion and safety profile of a brain‐shuttled crystallizable fragment‐silenced CD20 antibody

2025 · Schumacher, Vanessa L, Pichereau, Solen, et al. · Zurich Open Repository and Archive (University of Zurich)

PRO138 Insurance Claim-Based Algorithms to Identify Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) and Relapses – a Systematic Literature Review

2020 · S. Schneider, J. van Beek, et al. · Value in Health

Satralizumab in first incident treatment-naive aqp4-igg seropositive nmosd patients enrolled to sakurastar: A case series

2020 · J Palace, Jeffrey Bennett, et al. · Multiple Sclerosis Journal

Effect of satralizumab on relapse severity in neuromyelitis optica spectrum disorder (NMOSD): results from the phase III sakura studies

2020 · Jacqueline Palace, Ingo Kleiter, et al. · Multiple Sclerosis Journal

The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry

2015 · H.-Christian von Büdingen, Feng Mei, et al. · The Journal of Experimental Medicine

Limbic encephalitis with antibodies to LGI1 is associated with an active intrathecal B cell response

2014 · Klaus Lehmann-Horn, Sarosh Irani, et al. · Journal of Neuroimmunology

S.58. Quod Erat Demonstrandum: Clonally Expanded Plasma Cells in the CSF of MS Patients Produce “Oligoclonal Bands”

2009 · H. Christian von Büdingen, Monica Gulati, et al. · Clinical Immunology

Works count: 25

Citation count: 489

H-index: 10

I10-index: 10